Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
there was talk awhile ago about not spending enough on marketing.
I'd say CBAI is getting the word out to the right people.
The Corcell banner is right there across the top of their website and is listed as a partner.
It's a pretty extensive website, but I can't seem to get a grasp of how big/small they are. Anyone know how much exposure these people have?
http://www.thehealthybelly.com/about_us.php
http://www.corcell.com/corcell-thehealthybelly.htm
I've heard that the company needs to buy at the bid during a buyback. Is there any truth to this? ... wishful thinking?
I like the $100 pps, and I wish it were this year, even if it takes 3 -5 years, I'll take it. Any thoughts on why you think this year, as opposed to estimated approval timeline of the FDA?
article dated August, 2010
"Arteriocyte says that it costs approximately $5000 per unit; however, increasing the scale of production should bring the price per unit down. The only thing needed to scale up production is approval by the FDA, and experts currently estimate that it may take 3 – 5 years for the approval process to be completed."
http://singularityhub.com/2010/08/04/arteriocyte-produces-artificial-blood-sends-to-fda-for-approval/#
The way I originally read the statement about CBAI behind the DW buyout offer, I was under the impression it was CCEL that announced CBAI's involvement. Do we know for sure who leaked this info in court? CBAI or CCEL?
So, CBAI is on the donor form for Osiris right? Looks like Osiris is 90 days away from having the worlds first approved stem cell therapy. This should be an exciting year.
Health Canada requests Osiris additional information on stem cell therapy Prochymal
PBR Staff Writer
Published 17 January 2011
Health Canada has requested additional information in support of Osiris Therapeutics’ application for approval of stem cell therapy Prochymal for the treatment of graft vs. host disease (GvHD).
Health Canada has given Osiris 90 days to answer certain questions raised during the review.
Osiris president and CEO Randal Mills said they intend to work with Health Canada to expeditiously provide them the additional information necessary to complete the application and make this important therapy available to patients in need.
Osiris Therapeutics' pipeline of internally developed biologic drug candidates under evaluation includes Prochymal for inflammatory, autoimmune and cardiovascular indications, as well as Chondrogen for arthritis in the knee.
Osiris and Genzyme formed a strategic alliance for the development and commercialization of Prochymal and Chondrogen.
Under the terms of the agreement, Osiris retains commercialization rights to Prochymal and Chondrogen in the US and Canada.
Genzyme holds these rights in all other countries except Japan, where JCR Pharmaceuticals holds rights to Prochymal for the treatment of patients with hematological malignancies.
Last year, Health Canada has granted Prochymal Priority Review.
http://regulatoryaffairs.pharmaceutical-business-review.com/news/health-canada-requests-osiris-additional-information-on-stem-cell-therapy-prochymal-170111#
oh wow, my fault. it was early this morning. can't believe i did that. mod's should delete it
wow. i read most of what you posted, until you did the edit and removed it. corcell just got crushed. they should be forced out of business after reading that. if the general public saw this info, no one would ever store with Corcell. so what i got out of it was:
- corcell misled investors for years
- corcell technology is unsafe/not reliable
- corcell affiliates are pissed! and would gladly join someone like CBAI. easy to see how cryocell Europe could be next, especially with Dr. Oneil connection.
what i don't understand:
- the whole document has CBAI on the offense, with Corcell as the defendants. I thought Corcell filed the lawsuit?
- where is Corcells defense?
- CBAI is asking for compensation for the damages caused by Corcell. How? They proved how much cryocell sucks, but for what purpose? was CBAI a shareholder in Corcell?
could CBAI triple in size and reduce share count all at once with the help of DWHP?
purchase CC de Mex.
share buy back.
uplist to higher exchange.
it's what has been alluded to for months here, but I'm finally starting to think it could happen.
Exactly. And if you look at their website, you can see there is a strong relationship building process that occurs before the funding is provided for the acquisition. DWHP already went through the introductions and DD of CBAI, it would be easy to switch targets from CCEL to CC de Mex.
Another great part about DWHP,
Post Closing
Once the deal is finalized, we work with the management team to increase shareholder value. We leave the daily management of the business to the management team. Our investment team serves as board members and we leverage our industry expertise, deal origination activities and business relationships to help positively impact and grow the business.
We work together to identify, contact and acquire add-on acquisitions. Typically, we build out the sales and accounting infrastructure during the first few years of ownership.
http://dwhp.com/?a=about_dealprocess
I never realized what exactly DWHP was all about.
About DW Healthcare Partners
DW Healthcare Partners is a private equity firm focused exclusively on the healthcare industry. The firm manages over $250 million in committed capital and invests in profitable healthcare companies with proven management teams. DW Healthcare Partners is led by seasoned healthcare executives with more than 100 years of combined industry experience. The firm provides the capital, strategic guidance, and acquisition expertise to help mid-to late-stage companies realize their potential for growth.
http://dwhp.com/?a=about
you're being rediculous. the point was, both Pfizer and CBAI are tied to AHIP. It has been shown that Pfizer is very interested in stem cell research, and it just so happens CBAI is in the business of storing stem cells. So yes, it can be said that Pfizer is interested in all stem storage companies. However, CBAI is the only one with the AHIP relationship. This is why this is something to keep in mind and investigate further. If there was already a contract, we would not be having this conversation, I would be on one hell of a vacation. The goal is to get in before these major events take place, not after.
I think Pfizer's stem cell policy answers your question... of course they are interested.
http://www.pfizer.com/research/research_clinical_trials/stem_cell_research.jsp
Pfizer's Stem Cell Research Policy
When people think of human embryonic stem cells, they don't often imagine the power of these cells in drug discovery.
For more than a decade, Pfizer has been using animal or adult stem cells in its laboratories to help screen new compounds and identify safer and more effective medicines.
With compelling evidence from this research, Pfizer has begun to explore accessing drug development technology from leading academic, biotechnology or pharmaceutical partners around the world, who also have experience with currently-available, human embryonic stem cell lines that meet the highest ethical standards set by leading scientific authorities. This Pfizer Stem Cell Policy guides the company's research activities and its exploration of new external partnerships. The policy summary follows:
Pfizer recognizes the enormous potential of stem cell research. Stem cells are important tools for modern biomedical research, including Pfizer's search for innovative new medicines.
Pfizer has made significant investments in animal stem cells and in human adult hematopoietic (somatic) stem cells. The company will continue to invest in these stem cell technologies.
Pfizer recognizes that human embryonic stem cells may provide even greater potential due to their increased ability for self-renewal and capacity to form a wide variety of cells and tissues.
Pfizer acknowledges the sensitive issues raised by this research, and we support proper ethical safeguards that take into account both the moral issues and public sensitivities.
Pfizer will only engage in stem cell research projects that meet the highest ethical standards set by leading scientific authorities around the world, including the Guidelines developed by the National Academy of Sciences in the USA.
Pfizer strongly opposes any efforts to clone human beings.
Funny you mention BP.
I read that old presentation Matt made to potential investors (someone posted it yesterday). He said he wants to run CBAI like it is an oil and gas business. To control the supply, instead of hoping to strike oil, like so many other companies out there. I like the comparison.
Besides, that other stock has been rising ever since it plummeted. Do you think those investors are still worried about the spill? or have they moved on and are now looking to the future? The chart says they are looking to the future. I'll do the same with CBAI. It's not about the start up debt, or acquisition debt, or share count. It's about where the company will go from here. I believe CBAI is storing a valuable supply of stems. Sooner or later, it's got to pay off.
I agree. However, I think Matt would see your advice as wasted overhead. He is all about running lean.... increasing number of stems stored but keeping overhead down, which is why he is so interested in acquisitions. It is cheaper to just buy the stems in bulk from a competitors storage than to spend money trying to get every stem one at a time. Advertising gets expensive, and perhaps he does not think the return on investment is there, yet.
As much as I would like to see commercials and billboards with the Corcell logo, I am ok with the current strategy. First, get the stem inventory. Second, ad campaign to promote services. It will be much easier to spend money on advertising once CBAI is running off its own cashflow.
Obviously, if there is a very cheap way to improve IR and advertising, I'd say go for it. But my guess is this has already been evaluated and the current system gives the best ROI for what they are willing to spend.
all IMO, of course.
how can you say they might be cash flow positive and "your dreaming" in the same breath? cash flow positive is the first milestone we are waiting for. if you acknowledge it will probably happen soon, why do you insist on saying we are dreaming?
my email to IR
Dear Mr. xxxx:
Thanks for the email and being a CBAI investor. Yes, we are looking at the other opportunities in stem cells, specifically the ones referenced below. Those are mesenchymal stem cells (MSC’s), and they regenerate tissue. We launched our first foray into that space with the contract to collect placentas. In our goals for 2011, we stated one of the three goals is to continue to diversify revenue streams, and we are very bullish on the cellular pharmacy revenue stream, specifically MSC’s.
The parents own the cells. There is a problem though and that is the law. This could be construed as “selling” body parts. Like selling kidneys or limbs. It’s a slippery slope and right now the law is not in our favor. We have looked at this model for years now. We believe that in the next couple of years, demand will become so great that the laws will have to change. We also believe there is wiggle room in the current laws. For CBAI, we want to get profitable first before we pick long and drawn out battles. But this might be one we pick.
Thanks for the email and Merry Christmas.
MS
Mr. Schissler,
I Just read the December 23rd post regarding stem cells being used to treat Diabetes, hair loss, and to fight HIV. As a CBAI investor, these are very exciting times. CBAI as I know it today is mostly based around cord blood storage. Are there plans to evolve into a more wide spread stem cell company? I am just curious how CBAI is going to take advantage of these new developments in stem cell research. With the global footprint CBAI has achieved over the past year, it seems logical that it could lead the way with a revolutionary new business. Like an international pharmacy of all types of stem cells.
If CBAI became a broker of sorts, it would give the customer the option to make their cells available for sale at a later date if they decided they no longer needed them. Has CBAI considered this?
Recent CBAI IR blog post. This backs up my previous post. You know CBAI is aware of all these advances, so the question is... how will they take advantage of it and get a piece of that pie. I can't wait for the day the answer to this is released in a PR.
Much Recent News on the Benefits of Stem Cell Technology
Thursday, 23 December 2010 16:36 Written by Admin
December 23, 2010 - Many companies vested in stem cell technology are being rewarded with promising, new discoveries in this field that compare with science fiction coming true. Recent stem cell discoveries have ranged from the creation of a fully functioning intestine to a patient in Berlin, believed to be the first person fully cured of HIV, the virus that causes AIDS.
The researchers at the Cincinnati Children's Hospital Medical Center have said that the intestine they have created in a laboratory, using stem cells, is a fully functioning intestine that was able to defend itself against harmful bacteria. The implication of this discovery, is that the same procedure might someday be used in medicine to transplant new intestinal tissue.
Just this week, at the annual meeting of the American Society for Cell Biology, researchers from Georgetown University Medical Center in Washington, D.C., announced that it may be possible for people with type 1 diabetes to grow their own insulin-producing cells.
In the December issue of the medical journal Blood, researchers in Germany announced that they had used Adult Stem Cell therapy to cure a man afflicted with both leukemia and HIV. In 2007, a 44 year old patient volunteered to receive an experimental adult stem cell therapy to treat his leukemia. At the same time, the researchers decided to perform a stem-cell transplant in an effort to fight his HIV. The stem cell donor was a good blood match for the patient but in addition, he also had what the doctor's determined was a gene mutation that demonstrated a natural resistance to HIV. Many medical experts are showing strong interest in this case, whether it be pessimism or optimism. Dr. David Scadden, co-director of the Harvard University Stem Cell Institute did say, "But this is very encouraging… from all indications, there was no residual virus… It's as good an outcome as one could hope for."
Here's yet another field where stem cells are creating a buzz – researchers at the Berlin Technical University in Germany have grown the world's first artificial hair follicles from stem cells. One of the researches who led the study said within five years millions of hair-loss sufferers could grow new hair from their own stem cells and have it implanted in their bald spots. He also told the German newspaper, Die Welt, that preparations for clinical trials were "already in motion." Additionally he stated that since the 1950's the number of new chemicals used in cosmetics has increased 500-fold, and so has the need for animals to be experimented upon to ensure they are safe for humans. This could well do away with both these needs.
We are indeed experiencing exciting times in the stem cell industry and as more research is conducted more possibilities arise in different fields as does the potential for stem cells to be utilized to treat and cure diseases that were once thought to be incurable.
--------------------------------------------------------------------------------
http://www.cordblood-america.com/investors/ir-blog/192-much-recent-news-on-the-benefits-of-stem-cell-technology-
The problem is, selling the cord blood privately would be like selling body parts. I think this will happen eventually, but it will take some time to modify the current laws. IMO, it is inevitable. It will happen. And if CBAI wants to be a dominant stem cell company with diversified revenue, they will be at the front of the line to take advantage of this new industry. They are still laying the groundwork, creating the global footprint and building key relationships. It is only a matter of time. I wish I had more shares.
thats from 2006 and in no way even mentions CBAI.
Nite looks pretty content buying at 46, but he is selling at 50 so maybe up your bid to 50...
i'd just let it sit there and walk away, price seems pretty stable where its at. it should fill eventually
with so many shares out, how can it move so easily? down 6% on only 3MM traded?
6.8 million didnt seem to affect it though. thats a good sign. pretty strong support
if you're not interested in buying CBAI shares, what is your purpose here?
normally the MM's are all stacked at the same price. now they are spread out. 46, 47, 48, 49.... very thin.
wonder what changed all of a sudden. just need some volume now
Could be insurance, but I'd take hospitals as well.
Matthew Schissler, CEO, President and co-founder, said Cryo-Cell Mexico has more than 70,000 customers, operates in 32 states in Mexico with 13 affiliates, and has "an impressive, outstanding business model in partnering with hospitals."
could this be the supplier?
http://www.saneron-ccel.com/
again, you are seriously saying this is fake?
http://www.facebook.com/CryoCellMexico#!/photo.php?fbid=313745830456&set=a.313743980456.326586.244514110456
are the people in these pics photoshop too?
http://www.facebook.com/CryoCellMexico#!/album.php?aid=407274&id=244514110456
or how about the lab?
http://www.facebook.com/CryoCellMexico#!/album.php?aid=285720&id=244514110456
don't even know why this is being discussed. the place does exist and is dominating the country of Mexico in storage. who cares what it looks like.
point is,
#1, get profitable. Mexico deal will be a huge step to achieve this very soon.
#2, once profitable, do something major to get on a higher exchange. he specifically mentions strategic investors. seems to me an OS correction is going to happen, no doubt about it. and this mention of strategic investors was in the same sentance as the "bold move" that would get us to the higher exchange. I agree that it is unlikely to get there with the current OS, which is why I am pretty confident a buyback will happen. after all, why would they be seeking strategic investors just to do an R/S? doesnt make sense.
I see daily comments about the knock me over with a feather remark, so I read it again. Thought it was worth reposting.
Matt Schissler A quick comment to the last two questions: I understand where they come from. Investor frustration. Stock is down, so the "boo birds" come out. To them I ask: Do you truly believe that CBAI management wants to stock to be where it is? If you do, you need your e-trade account taken away. Outside of that, you must ...know that the management works tirelessly here. We know what we need to do. 1. get profitable, and 2. create an earth shaking event that affects our cap structure. Doing both of these get us out of being in the penny stock "do-loop." Rocket up, leak down. In order to graduate to a larger board, the above two items need to be accomplished. We know this. We work unabated on this. There is no silver bullet. We're confident it will happen and it is our focus. In the interim, the ups and downs are frustrating), but it does not deter us from accomplishing what we repeatedly have said, to be the world's largest, most significant stem cell storage company.
Matt Schissler Is it a goal of the company moving forward to attract institutional investment for even further expansion/aquisition opportunities?
ANS: Yes. this goes hand in hand with the previous question. We have institutional investment, as it is a generic term. What we seek is strategic investment. We believe now is the time... to stop being a penny stock, to attract strategic investors, and to make a bold move that no one would have even fathomed we could do. We made a bold move in late 2006, by buying CorCell. An industry insider said "you could have knocked me over with a feather..." when she heard the news. We were tiny. No one thought we could have pulled it off. We did. I've said all year we have a voracious appetite. I said all year about growth, acquisition, diversification. We've made those moves so far. But a strategic investment allows us to have another feather knock down moment again. That's the focus. Voracious appetite.See
Matt Schissler Is a potential uplisting to a reputable exchange written anywhere within CBAI's strategic growth strategy for success?
ANS: Great question Antonio. Disclaimer - since I have not revealed a specific strategy publicly, I need to keep this generic. 1. Yes. The CBAI management has no desire to stay on the BB forever. ... We're almost six years of fully reporting on the OTCBB. It has its advantages over larger exchanges, which has helped us accomplish what we have so far. But it's time to graduate from the OTCBB, provided we meet the larger requirements of a national exchange. The goal is to get to a national exchange, sooner rather than later. We need to meet national exchange requirements. There is a much larger strategy behind this, one I believe the shareholders will foam at the mouth for. Stay tuned. That is all I can say right now
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=53732396
I would think so. Its adding 8 or 9 million dollars in revenue. I guess it depends on how it is purchased. If financed, could it cost more than 8 or 9MM a year? I think I saw the purchase price was around 20MM.
It makes sense now that I see where that 14MM number came from.
revenue for past 9 months was about 2.7MM, so thats about 3.6MM for a year.
3.6MM*3 = 10.8MM
still a little short, but prob cus there was less revenue earlier in the year.
"CBAI would triple size with Mexico stem cell storage acquisition"
this is the headline of the PR if you get it from the CBAI website.
http://www.cordblood-america.com/cbai-news/186-cord-blood-america-otc-bb-cbai-would-triple-size-with-mexico-stem-cell-storage-acquisition-
also,
"Further commenting about being acquisitive, Mr. Schissler added, "Day-to-day conversations are ongoing, regarding acquisition opportunities. It's a sign that the industry is consolidating and an effort that we are committed to staying front and center on.""
were not done yet, more acquisitions to come!
exactly! the board is dominated by garbage. this is the type of topic that I prefer to read.... the impact of acquisitions and possible future developments.
any thoughts on why cryocell would give up Mexico to CBAI? think there might be additional cryocell affiliates taken over?
Cryocell Mexico is still listed on the Cryocell international webpage.
http://www.cryo-cell.com/company/affiliates.asp
If your company was called cryocell International, why would you sell one of the affiliates?
And in every other case so far, the aquired company has maintained its brand name. What will happen here? Think the name will change to Corcell? There's no chance of CBAI acquiring more Corcell affiliates, is there? Now that would be a feather moment, if CBAI continues buying up all Corcell affiliates. Dreaming?....
What I like most about this PR vs some of the previous ones, there are some solid numbers provided regarding the impact of the aquisition.
"The acquisition, when completed, means that Cord Blood America will control over 100,000 customers internationally, and expects its combined revenues to be in the $14M range annually if all businesses continue the same sales rate.
Cryo-Cell Mexico has averaged over 8,000 new customers per year, for the last three years. "
The minimum payment plan is $150 at enrollment plus $53/month.
8000*150 = $1.2MM
8000*53*12 = $5MM (per year for 4 years)
After 4 years, CBAI pulls in at least $24.8MM. Considering the purchase price is under $20MM, that is amazing.
have a bid in for at least 5 minutes now for 212K shares @ 42 and its not filling. do they intentionally not fill orders?
edit: finally filled after about 10 min on the ask
I checked out that link and this paragraph stood out to me. Whats this about the stock purchase agreement? Was there a stock purchase in the past, or could this be new info?
"Since launching Cord Blood America, Matt has been instrumental in raising over $20M for the business, using these funds to complete three asset purchases and one stock purchase agreement."
if you go to the Vita34 website, there is an option for German or English, however the link for English results in no page found. wonder if that english page is new.
http://www.vita34.de/vita/en/
does it mean anything that CSTI is so active in this stock? Collins Stewert is out of the U.K. Is that normal for a European company to be so heavily involved in trading a U.S. security (especially a penny stock)?